Share Price and Basic Stock Data
Last Updated: November 7, 2025, 4:06 pm
| PEG Ratio | 1.27 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Beta Drugs Ltd operates within the pharmaceuticals sector, with a current market capitalization of ₹1,889 Cr and a share price of ₹1,872. The company recorded an impressive revenue growth trajectory, with sales rising from ₹51 Cr in March 2018 to ₹362 Cr in March 2025, reflecting a compound annual growth rate (CAGR) of approximately 32.4%. This growth is supported by consistent quarterly sales increases, peaking at ₹141 Cr in September 2023 and projected to reach ₹180 Cr by September 2024. The operating profit margin (OPM) has remained relatively stable, recorded at 20% currently, indicating effective cost management amidst rising sales. The company’s ability to maintain sales growth, even in challenging market conditions, positions it favorably against typical sector norms, which often cite lower growth rates. Furthermore, the absence of other income until recently highlights a focus on core operational performance, reinforcing the company’s commitment to its primary business activities.
Profitability and Efficiency Metrics
Beta Drugs Ltd’s profitability metrics illustrate a robust financial performance, with a reported net profit of ₹42 Cr for the fiscal year ending March 2025, compared to ₹7 Cr in March 2018. This significant leap has led to a net profit margin of 11.70% as of March 2025, slightly below the sector average, which is often around 12-15%. The company’s return on equity (ROE) stood at 25.9%, showcasing efficient use of equity capital, while the return on capital employed (ROCE) was reported at 27%. Efficiency ratios, such as the cash conversion cycle (CCC) of 79 days, demonstrate effective management of working capital, although the debtor days increased to 103, indicating potential areas for improvement in receivables management. The interest coverage ratio (ICR) of 11.60x further highlights the company’s ability to cover its interest expenses comfortably, positioning it well against financial pressures.
Balance Sheet Strength and Financial Ratios
The balance sheet of Beta Drugs Ltd reflects a solid foundation, with total assets reported at ₹436 Cr as of March 2025. The company’s reserves have increased substantially, reaching ₹187 Cr, indicating strong retained earnings that support future growth initiatives. However, borrowings have also risen to ₹138 Cr, reflecting a long-term debt to equity ratio of 0.64, which is relatively low compared to industry norms, suggesting prudent leverage. The current ratio stood at 3.22, indicating a strong liquidity position, well above the typical threshold of 1.5, which allows for adequate short-term obligations coverage. Additionally, the price-to-book value (P/BV) ratio of 9.76x suggests that the stock is trading at a premium, reflecting investor confidence in future growth. Nonetheless, the enterprise value (EV) to EBITDA ratio of 23.56 indicates that the stock may be considered overvalued relative to its earnings potential, warranting careful consideration by investors.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Beta Drugs Ltd reveals a strong promoter holding of 66.73%, which reflects a significant level of commitment and confidence from the company’s founders. Foreign institutional investors (FIIs) and domestic institutional investors (DIIs) hold minor stakes of 0.90% and 0.26%, respectively, which suggests limited institutional interest. However, the public shareholding has seen an increase, with the number of shareholders rising to 3,139 as of March 2025, compared to 1,407 in September 2022. This growth indicates increasing retail investor interest, which is a positive sign for market sentiment. The gradual increase in FIIs’ shareholding, from 0.29% to 0.90%, may reflect growing confidence in the company’s growth trajectory. Maintaining a healthy balance between promoter and public ownership is crucial for corporate governance and can enhance investor confidence moving forward.
Outlook, Risks, and Final Insight
Looking ahead, Beta Drugs Ltd is well-positioned for continued growth, bolstered by strong sales trends and profitability metrics. However, the company faces certain risks, including rising operational costs that may pressure margins, as evidenced by the increase in expenses from ₹174 Cr in March 2023 to ₹288 Cr in March 2025. Additionally, the increasing debtor days may pose risks to cash flow management, necessitating improved receivables collection strategies. On the positive side, the company’s solid balance sheet and healthy liquidity position provide a buffer against economic fluctuations. Furthermore, the increasing public shareholder base can enhance liquidity and market perception. Ultimately, Beta Drugs Ltd’s growth outlook remains contingent upon its ability to manage costs and optimize operational efficiency while capitalizing on its strong market position in the pharmaceutical sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Beta Drugs Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 142 Cr. | 113 | 247/84.3 | 32.4 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.63 Cr. | 1.90 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,887 Cr. | 449 | 479/192 | 110 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.8 Cr. | 44.2 | 92.2/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 36.5 Cr. | 24.9 | 29.1/17.0 | 38.0 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,616.33 Cr | 1,177.66 | 56.64 | 197.44 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Sep 2019 | Mar 2020 | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 47 | 44 | 51 | 65 | 88 | 96 | 112 | 115 | 141 | 154 | 180 | 182 |
| Expenses | 37 | 36 | 41 | 51 | 68 | 73 | 86 | 88 | 108 | 127 | 141 | 146 |
| Operating Profit | 9 | 8 | 11 | 14 | 20 | 23 | 27 | 26 | 33 | 27 | 39 | 36 |
| OPM % | 20% | 19% | 21% | 22% | 23% | 24% | 24% | 23% | 23% | 18% | 22% | 20% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 0 |
| Interest | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 5 |
| Depreciation | 2 | 2 | 3 | 4 | 3 | 4 | 5 | 6 | 5 | 4 | 6 | 7 |
| Profit before tax | 7 | 5 | 7 | 9 | 16 | 18 | 21 | 20 | 27 | 22 | 33 | 24 |
| Tax % | 27% | 14% | 21% | 30% | 28% | 27% | 25% | 25% | 25% | 25% | 25% | 26% |
| Net Profit | 5 | 4 | 5 | 7 | 12 | 13 | 16 | 15 | 20 | 17 | 24 | 18 |
| EPS in Rs | 5.07 | 4.25 | 5.13 | 6.48 | 11.63 | 12.95 | 15.67 | 14.73 | 19.67 | 16.40 | 24.20 | 17.81 |
Last Updated: May 31, 2025, 9:40 am
Below is a detailed analysis of the quarterly data for Beta Drugs Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 182.00 Cr.. The value appears strong and on an upward trend. It has increased from 180.00 Cr. (Sep 2024) to 182.00 Cr., marking an increase of 2.00 Cr..
- For Expenses, as of Mar 2025, the value is 146.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 141.00 Cr. (Sep 2024) to 146.00 Cr., marking an increase of 5.00 Cr..
- For Operating Profit, as of Mar 2025, the value is 36.00 Cr.. The value appears to be declining and may need further review. It has decreased from 39.00 Cr. (Sep 2024) to 36.00 Cr., marking a decrease of 3.00 Cr..
- For OPM %, as of Mar 2025, the value is 20.00%. The value appears to be declining and may need further review. It has decreased from 22.00% (Sep 2024) to 20.00%, marking a decrease of 2.00%.
- For Other Income, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Sep 2024) to 0.00 Cr., marking a decrease of 2.00 Cr..
- For Interest, as of Mar 2025, the value is 5.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.00 Cr. (Sep 2024) to 5.00 Cr., marking an increase of 3.00 Cr..
- For Depreciation, as of Mar 2025, the value is 7.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6.00 Cr. (Sep 2024) to 7.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Mar 2025, the value is 24.00 Cr.. The value appears to be declining and may need further review. It has decreased from 33.00 Cr. (Sep 2024) to 24.00 Cr., marking a decrease of 9.00 Cr..
- For Tax %, as of Mar 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 25.00% (Sep 2024) to 26.00%, marking an increase of 1.00%.
- For Net Profit, as of Mar 2025, the value is 18.00 Cr.. The value appears to be declining and may need further review. It has decreased from 24.00 Cr. (Sep 2024) to 18.00 Cr., marking a decrease of 6.00 Cr..
- For EPS in Rs, as of Mar 2025, the value is 17.81. The value appears to be declining and may need further review. It has decreased from 24.20 (Sep 2024) to 17.81, marking a decrease of 6.39.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: June 16, 2025, 5:58 pm
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Sales | 51 | 66 | 91 | 116 | 184 | 227 | 296 | 362 |
| Expenses | 41 | 54 | 73 | 91 | 141 | 174 | 236 | 288 |
| Operating Profit | 9 | 12 | 18 | 25 | 43 | 53 | 60 | 75 |
| OPM % | 19% | 18% | 20% | 21% | 23% | 23% | 20% | 21% |
| Other Income | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 |
| Interest | 1 | 1 | 3 | 2 | 2 | 2 | 3 | 7 |
| Depreciation | 2 | 3 | 4 | 7 | 7 | 10 | 10 | 13 |
| Profit before tax | 7 | 8 | 12 | 16 | 34 | 41 | 49 | 57 |
| Tax % | 1% | -2% | 21% | 27% | 28% | 25% | 25% | 26% |
| Net Profit | 7 | 8 | 9 | 12 | 25 | 31 | 36 | 42 |
| EPS in Rs | 7.43 | 8.84 | 9.33 | 11.60 | 24.58 | 30.42 | 36.08 | 42.02 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 14.29% | 12.50% | 33.33% | 108.33% | 24.00% | 16.13% | 16.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | -1.79% | 20.83% | 75.00% | -84.33% | -7.87% | 0.54% |
Beta Drugs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 32% |
| 3 Years: | 25% |
| TTM: | 23% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 37% |
| 3 Years: | 23% |
| TTM: | 26% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 87% |
| 3 Years: | 36% |
| 1 Year: | 12% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 26% |
| 3 Years: | 27% |
| Last Year: | 26% |
Last Updated: September 5, 2025, 12:45 am
Balance Sheet
Last Updated: October 10, 2025, 1:44 pm
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 24 | 32 | 48 | 59 | 83 | 113 | 148 | 187 |
| Borrowings | 8 | 20 | 23 | 17 | 21 | 20 | 15 | 138 |
| Other Liabilities | 9 | 22 | 28 | 31 | 45 | 55 | 82 | 101 |
| Total Liabilities | 50 | 83 | 107 | 118 | 158 | 198 | 254 | 436 |
| Fixed Assets | 13 | 18 | 44 | 40 | 55 | 63 | 65 | 89 |
| CWIP | 1 | 15 | 0 | 3 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 |
| Other Assets | 35 | 50 | 63 | 74 | 102 | 135 | 190 | 347 |
| Total Assets | 50 | 83 | 107 | 118 | 158 | 198 | 254 | 436 |
Below is a detailed analysis of the balance sheet data for Beta Drugs Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 10.00 Cr..
- For Reserves, as of Mar 2025, the value is 187.00 Cr.. The value appears strong and on an upward trend. It has increased from 148.00 Cr. (Mar 2024) to 187.00 Cr., marking an increase of 39.00 Cr..
- For Borrowings, as of Mar 2025, the value is 138.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 15.00 Cr. (Mar 2024) to 138.00 Cr., marking an increase of 123.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 101.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 82.00 Cr. (Mar 2024) to 101.00 Cr., marking an increase of 19.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 436.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 254.00 Cr. (Mar 2024) to 436.00 Cr., marking an increase of 182.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 89.00 Cr.. The value appears strong and on an upward trend. It has increased from 65.00 Cr. (Mar 2024) to 89.00 Cr., marking an increase of 24.00 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 347.00 Cr.. The value appears strong and on an upward trend. It has increased from 190.00 Cr. (Mar 2024) to 347.00 Cr., marking an increase of 157.00 Cr..
- For Total Assets, as of Mar 2025, the value is 436.00 Cr.. The value appears strong and on an upward trend. It has increased from 254.00 Cr. (Mar 2024) to 436.00 Cr., marking an increase of 182.00 Cr..
Notably, the Reserves (187.00 Cr.) exceed the Borrowings (138.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 1.00 | -8.00 | -5.00 | 8.00 | 22.00 | 33.00 | 45.00 | -63.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 104 | 139 | 128 | 106 | 90 | 101 | 98 | 103 |
| Inventory Days | 37 | 104 | 102 | 100 | 87 | 106 | 122 | 127 |
| Days Payable | 81 | 143 | 119 | 127 | 123 | 139 | 145 | 152 |
| Cash Conversion Cycle | 60 | 100 | 111 | 79 | 53 | 68 | 75 | 79 |
| Working Capital Days | 50 | 40 | 56 | 76 | 61 | 73 | 80 | 82 |
| ROCE % | 18% | 21% | 22% | 36% | 34% | 33% | 27% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 42.02 | 37.90 | 31.95 | 25.82 | 12.20 |
| Diluted EPS (Rs.) | 42.02 | 37.90 | 31.95 | 25.82 | 12.20 |
| Cash EPS (Rs.) | 54.42 | 48.08 | 42.78 | 33.37 | 19.34 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 195.25 | 163.43 | 127.82 | 96.05 | 71.37 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 195.25 | 163.43 | 127.82 | 96.05 | 71.37 |
| Revenue From Operations / Share (Rs.) | 358.96 | 307.59 | 236.24 | 191.22 | 120.79 |
| PBDIT / Share (Rs.) | 80.28 | 63.82 | 56.05 | 45.20 | 26.26 |
| PBIT / Share (Rs.) | 67.89 | 53.65 | 45.22 | 37.65 | 19.11 |
| PBT / Share (Rs.) | 56.44 | 50.71 | 42.70 | 35.68 | 16.59 |
| Net Profit / Share (Rs.) | 42.02 | 37.90 | 31.95 | 25.82 | 12.20 |
| NP After MI And SOA / Share (Rs.) | 42.02 | 37.90 | 31.95 | 25.82 | 12.20 |
| PBDIT Margin (%) | 22.36 | 20.74 | 23.72 | 23.63 | 21.73 |
| PBIT Margin (%) | 18.91 | 17.44 | 19.14 | 19.69 | 15.81 |
| PBT Margin (%) | 15.72 | 16.48 | 18.07 | 18.65 | 13.73 |
| Net Profit Margin (%) | 11.70 | 12.32 | 13.52 | 13.50 | 10.09 |
| NP After MI And SOA Margin (%) | 11.70 | 12.32 | 13.52 | 13.50 | 10.09 |
| Return on Networth / Equity (%) | 21.52 | 23.19 | 24.99 | 26.88 | 17.08 |
| Return on Capital Employeed (%) | 20.54 | 30.43 | 32.10 | 33.24 | 22.09 |
| Return On Assets (%) | 9.72 | 14.33 | 15.48 | 15.72 | 9.97 |
| Long Term Debt / Equity (X) | 0.64 | 0.03 | 0.05 | 0.12 | 0.16 |
| Total Debt / Equity (X) | 0.67 | 0.06 | 0.13 | 0.17 | 0.21 |
| Asset Turnover Ratio (%) | 1.05 | 1.31 | 1.27 | 1.09 | 0.82 |
| Current Ratio (X) | 3.22 | 2.10 | 2.03 | 1.98 | 1.99 |
| Quick Ratio (X) | 2.64 | 1.51 | 1.54 | 1.52 | 1.53 |
| Inventory Turnover Ratio (X) | 3.21 | 4.17 | 4.16 | 5.70 | 4.47 |
| Interest Coverage Ratio (X) | 11.60 | 21.76 | 22.31 | 22.88 | 10.43 |
| Interest Coverage Ratio (Post Tax) (X) | 7.72 | 13.92 | 13.72 | 14.07 | 5.85 |
| Enterprise Value (Cr.) | 1909.20 | 1168.47 | 599.62 | 542.92 | 119.61 |
| EV / Net Operating Revenue (X) | 5.27 | 3.95 | 2.64 | 2.95 | 1.03 |
| EV / EBITDA (X) | 23.56 | 19.04 | 11.13 | 12.49 | 4.74 |
| MarketCap / Net Operating Revenue (X) | 5.31 | 4.01 | 2.65 | 2.96 | 0.99 |
| Price / BV (X) | 9.76 | 7.55 | 4.90 | 5.89 | 1.68 |
| Price / Net Operating Revenue (X) | 5.31 | 4.01 | 2.65 | 2.96 | 0.99 |
| EarningsYield | 0.02 | 0.03 | 0.05 | 0.04 | 0.10 |
After reviewing the key financial ratios for Beta Drugs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 42.02. This value is within the healthy range. It has increased from 37.90 (Mar 24) to 42.02, marking an increase of 4.12.
- For Diluted EPS (Rs.), as of Mar 25, the value is 42.02. This value is within the healthy range. It has increased from 37.90 (Mar 24) to 42.02, marking an increase of 4.12.
- For Cash EPS (Rs.), as of Mar 25, the value is 54.42. This value is within the healthy range. It has increased from 48.08 (Mar 24) to 54.42, marking an increase of 6.34.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 195.25. It has increased from 163.43 (Mar 24) to 195.25, marking an increase of 31.82.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 195.25. It has increased from 163.43 (Mar 24) to 195.25, marking an increase of 31.82.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 358.96. It has increased from 307.59 (Mar 24) to 358.96, marking an increase of 51.37.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 80.28. This value is within the healthy range. It has increased from 63.82 (Mar 24) to 80.28, marking an increase of 16.46.
- For PBIT / Share (Rs.), as of Mar 25, the value is 67.89. This value is within the healthy range. It has increased from 53.65 (Mar 24) to 67.89, marking an increase of 14.24.
- For PBT / Share (Rs.), as of Mar 25, the value is 56.44. This value is within the healthy range. It has increased from 50.71 (Mar 24) to 56.44, marking an increase of 5.73.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 42.02. This value is within the healthy range. It has increased from 37.90 (Mar 24) to 42.02, marking an increase of 4.12.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 42.02. This value is within the healthy range. It has increased from 37.90 (Mar 24) to 42.02, marking an increase of 4.12.
- For PBDIT Margin (%), as of Mar 25, the value is 22.36. This value is within the healthy range. It has increased from 20.74 (Mar 24) to 22.36, marking an increase of 1.62.
- For PBIT Margin (%), as of Mar 25, the value is 18.91. This value is within the healthy range. It has increased from 17.44 (Mar 24) to 18.91, marking an increase of 1.47.
- For PBT Margin (%), as of Mar 25, the value is 15.72. This value is within the healthy range. It has decreased from 16.48 (Mar 24) to 15.72, marking a decrease of 0.76.
- For Net Profit Margin (%), as of Mar 25, the value is 11.70. This value exceeds the healthy maximum of 10. It has decreased from 12.32 (Mar 24) to 11.70, marking a decrease of 0.62.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 11.70. This value is within the healthy range. It has decreased from 12.32 (Mar 24) to 11.70, marking a decrease of 0.62.
- For Return on Networth / Equity (%), as of Mar 25, the value is 21.52. This value is within the healthy range. It has decreased from 23.19 (Mar 24) to 21.52, marking a decrease of 1.67.
- For Return on Capital Employeed (%), as of Mar 25, the value is 20.54. This value is within the healthy range. It has decreased from 30.43 (Mar 24) to 20.54, marking a decrease of 9.89.
- For Return On Assets (%), as of Mar 25, the value is 9.72. This value is within the healthy range. It has decreased from 14.33 (Mar 24) to 9.72, marking a decrease of 4.61.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.64. This value is within the healthy range. It has increased from 0.03 (Mar 24) to 0.64, marking an increase of 0.61.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.67. This value is within the healthy range. It has increased from 0.06 (Mar 24) to 0.67, marking an increase of 0.61.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.05. It has decreased from 1.31 (Mar 24) to 1.05, marking a decrease of 0.26.
- For Current Ratio (X), as of Mar 25, the value is 3.22. This value exceeds the healthy maximum of 3. It has increased from 2.10 (Mar 24) to 3.22, marking an increase of 1.12.
- For Quick Ratio (X), as of Mar 25, the value is 2.64. This value exceeds the healthy maximum of 2. It has increased from 1.51 (Mar 24) to 2.64, marking an increase of 1.13.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.21. This value is below the healthy minimum of 4. It has decreased from 4.17 (Mar 24) to 3.21, marking a decrease of 0.96.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 11.60. This value is within the healthy range. It has decreased from 21.76 (Mar 24) to 11.60, marking a decrease of 10.16.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.72. This value is within the healthy range. It has decreased from 13.92 (Mar 24) to 7.72, marking a decrease of 6.20.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,909.20. It has increased from 1,168.47 (Mar 24) to 1,909.20, marking an increase of 740.73.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 5.27. This value exceeds the healthy maximum of 3. It has increased from 3.95 (Mar 24) to 5.27, marking an increase of 1.32.
- For EV / EBITDA (X), as of Mar 25, the value is 23.56. This value exceeds the healthy maximum of 15. It has increased from 19.04 (Mar 24) to 23.56, marking an increase of 4.52.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 5.31. This value exceeds the healthy maximum of 3. It has increased from 4.01 (Mar 24) to 5.31, marking an increase of 1.30.
- For Price / BV (X), as of Mar 25, the value is 9.76. This value exceeds the healthy maximum of 3. It has increased from 7.55 (Mar 24) to 9.76, marking an increase of 2.21.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 5.31. This value exceeds the healthy maximum of 3. It has increased from 4.01 (Mar 24) to 5.31, marking an increase of 1.30.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Beta Drugs Ltd:
- Net Profit Margin: 11.7%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 20.54% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 21.52% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 7.72
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.64
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 37.3 (Industry average Stock P/E: 56.64)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.67
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 11.7%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Village Nandpur, Baddi Himachal Pradesh 174101 | cs@betadrugslimited.com http://www.betadrugslimited.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Rahul Batra | Chairperson & Managing Director |
| Mr. Varun Batra | Joint Managing Director |
| Mrs. Seema Chopra | Whole Time Director |
| Mr. Balwant Singh | Whole Time Director |
| Mr. Manmohan Khanna | Independent Director |
| Mr. Ashutosh Shukla | Whole Time Director |
| Mr. Rohit Parti | Independent Director |
FAQ
What is the intrinsic value of Beta Drugs Ltd?
Beta Drugs Ltd's intrinsic value (as of 07 November 2025) is 1726.41 which is 3.38% higher the current market price of 1,670.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 1,686 Cr. market cap, FY2025-2026 high/low of 2,215/1,430, reserves of ₹187 Cr, and liabilities of 436 Cr.
What is the Market Cap of Beta Drugs Ltd?
The Market Cap of Beta Drugs Ltd is 1,686 Cr..
What is the current Stock Price of Beta Drugs Ltd as on 07 November 2025?
The current stock price of Beta Drugs Ltd as on 07 November 2025 is 1,670.
What is the High / Low of Beta Drugs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Beta Drugs Ltd stocks is 2,215/1,430.
What is the Stock P/E of Beta Drugs Ltd?
The Stock P/E of Beta Drugs Ltd is 37.3.
What is the Book Value of Beta Drugs Ltd?
The Book Value of Beta Drugs Ltd is 219.
What is the Dividend Yield of Beta Drugs Ltd?
The Dividend Yield of Beta Drugs Ltd is 0.00 %.
What is the ROCE of Beta Drugs Ltd?
The ROCE of Beta Drugs Ltd is 27.0 %.
What is the ROE of Beta Drugs Ltd?
The ROE of Beta Drugs Ltd is 25.9 %.
What is the Face Value of Beta Drugs Ltd?
The Face Value of Beta Drugs Ltd is 10.0.